This new insulin might mean fewer injections and better blood sugar control — both up and down — for diabetes patients.

Q3 2024 Earnings Call Transcript October 16, 2024 Abbott Laboratories beats earnings expectations. Reported EPS is $1.21, ...

There are problems within the health system that mean full patient access to training on how to use the insulin pumps will ...

Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals. Click here to read ...

The smart contact lenses, which are currently in advanced stages of testing, represent a major shift in how healthcare can be ...

In recent years, digital health has become a new development trend in the global health and medical industry. By using ...

To meet international guidelines, New Zealand needs to double the workforce that supports people with diabetes. Unless that ...

Innovative fingertip biofuel cells and flexible thermoelectric devices enable non-invasive biomarker sensing and energy ...

Continuous glucose monitors (CGM), once exclusive to diabetics, are now available over-the-counter, opening new possibilities ...

Senseonics’ Eversense 365 is approved in the US as an integrated continuous glucose monitoring (iCGM) system for people with Type 1 and Type 2 ...

These DIY kits are a $5 billion industry. We report on the pros, the cons, and the ones to avoid at all costs.